Olanzapine + CORT118335 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antipsychotic-induced Weight Gain
Conditions
Antipsychotic-induced Weight Gain
Trial Timeline
Apr 1, 2019 → Mar 25, 2020
NCT ID
NCT03877562About Olanzapine + CORT118335 + Placebo
Olanzapine + CORT118335 + Placebo is a phase 1 stage product being developed by Corcept Therapeutics for Antipsychotic-induced Weight Gain. The current trial status is completed. This product is registered under clinical trial identifier NCT03877562. Target conditions include Antipsychotic-induced Weight Gain.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03877562 | Phase 1 | Completed |
Competing Products
2 competing products in Antipsychotic-induced Weight Gain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Miricorilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |